FutureTech II
Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal
Longevity Biotech; Nasdaq; SPAC deal; public listing; FutureTech II Acquisition Corp.; clinical development; biotech merger; age-related diseases
Actionable Insights Powered by AI
Longevity Biotech; Nasdaq; SPAC deal; public listing; FutureTech II Acquisition Corp.; clinical development; biotech merger; age-related diseases